| Prev Close | 18.90 |
| Open | 18.18 |
| Day Low/High | 17.95 / 18.84 |
| 52 Wk Low/High | 2.35 / 23.91 |
| Volume | 28.48M |
| Avg Volume | 6.89M |
Amarin Corp. Plc (AMRN)
18.08
0.82
4.34
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 330.64M |
| Market Cap | 6.25B |
| EPS | -0.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Stocks Take Flight on Dovish Fed Comments
Market players are trying to decipher Fed Chair Powell's latest words.
I Have My Eye on This Warren Buffett Stock Amid the Choppy Action
Market players are more skeptical of the quick moves on U.S.-China trade news.
Lyft's Aggressive IPO Pricing Was a Mistake
Poor trading action in Lyft will likely create some distrust of upcoming IPOs, and Uber in particular.
The Best Approach to Trading Lyft
Valuation and all the other issues that are being discussed are secondary to the price action.
Market Gains Some Momentum, Lululemon Breaks Out
While there is some positive movement, it has not been sustained which makes trading quite tricky.
The Market Worries About Global Growth but Looks for Progress on China Trade
China negotiations resume today and the potential for weekend news is high.
What Will Warren Buffett Say About Kraft Heinz?
So far there is no bounce in Kraft Heinz which is not a good sign.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
Facebook Is Today's Star as Pockets of Strong Momentum Grow
It is the action in secondary stocks that is giving the action a much better feel.
This Market May Just Be in an Uptrend: Market Recon
This is the kind of reversal that happens in a bull market.
CAT Stock Gets Thrown Into the Dumpster
This stock can become much cheaper if there is a major cycle turn occurring.
There Are No Safe Havens Right Now
The indices need to find support and we need some better pockets of strength.
Play Amarin's 'Home-Run Potential'
Latest trial results appear to show the biotech has a super fish oil pill with potential to aid those with high triglycerides.
Amarin Continues to Impress
The market continues to be flat as we enter the last hour of the trading week. It looks like the SCOTUS nomination fight will drag out for at least another divisive week as a couple of Republican senators cave in supporting another FBI investigatio...
Facebook Battles Negative Sentiment and a Weak Chart
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Another Day of Rotation, but of a Different Sort
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'
Sirius XM May Have Opened Pandora's Box With Takeover Announcement
The satellite radio operator's stock is declining after announcing the purchase of the streaming radio service.
Stocks Wake Up After Hard Selloff
Stock buyers are back after Thursdays selloff helped by Pandora's jump higher. Dell's disaster continues and China has a fat finger trade.
Amarin Stock May Be Worth the Wait
A growing and aging population ensures biotechs won't go out of style.
Futures Rise on Key Earnings
US stock futures are rising on strong earnings from DuPont and Coach, while Amarin gets a nod from the FDA - Debra Borchardt gives details.
The Next Big Thing in Biotech: J.P. Morgan Conference
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
The Next Big Thing in Biotech
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Catch a Ride if You Can
Be willing to chase this rally, even though it's disliked by so many market players.
The Next Big Thing in Biotech: FDA Approvals
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
